At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 141 enrolled
Drug / intervention
ABT-493, ABT-530 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Failed a Prior Direct-Acting Antiviral Agent (DAA)-Containing Therapy
In Brief
A Phase 3 clinical trial evaluating ABT-493, ABT-530, ribavirin (RBV), and 1 other intervention for Chronic Hepatitis C and 3 related conditions. Completed, enrolled 141 participants.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin (RBV) in participants with chronic hepatitis C virus, (HCV)-infection who previously failed treatment with a direct acting antiviral (DAA)-containing regimen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C, Hepatitis C Virus, HCV, Direct-Acting Antiviral Agent (DAA)-Experienced
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartApr 2015
First PostedMay 2015
Primary CompletionDec 2016
Study CompletionJan 2017
TodayJul 2026
First PostedMay 18, 2015
Enrollment StartApr 1, 2015
Primary CompletionDec 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.1 years ago
Interventions
ABT-493, ABT-530drug
ABT-493 (tablet) dosed with ABT-530 (tablet)
ribavirin (RBV)drug
Tablet
ABT-493/ABT-530drug
Tablet; ABT-493 coformulated with ABT-530